Liu, Si-Yang
Dong, Song
Yang, Xue-Ning http://orcid.org/0000-0002-8346-2117
Liao, Ri-Qiang
Jiang, Ben-Yuan
Wang, Qun
Ben, Xiao-Song
Qiao, Gui-Bin
Lin, Jun-Tao
Yan, Hong-Hong http://orcid.org/0000-0002-6228-2096
Yan, Li-Xu
Nie, Qiang
Tu, Hai-Yan
Wang, Bin-Chao
Yang, Jin-Ji
Zhou, Qing
Li, Hong-Rui
Liu, Ke
Wu, Wendy
Liu, Si-Yang Maggie
Zhong, Wen-Zhao http://orcid.org/0000-0002-8917-8635
Wu, Yi-Long http://orcid.org/0000-0002-3611-0258
Article History
Received: 24 May 2023
Revised: 3 November 2023
Accepted: 12 November 2023
First Online: 6 December 2023
Competing interests
: Y.-L.W. was a research consultant for AstraZeneca, and received research funding from Roche and speech honoraria from AstraZeneca, Roche, Eli Lilly, Pfizer, and Sanofi. W.-Z.Z. received speech honoraria from AstraZeneca, Roche, Eli Lilly, and Pfizer. H.-R.L., K.L., and W.W. are employees of Fujian Key Laboratory of Advanced Technology for Cancer Screening and Early Diagnosis and the Berry Oncology Corporation. All remaining authors declare no competing interests.